161 results on '"Quiroga, Dionisia"'
Search Results
2. Health Equity in Cardio-oncology: Investigating Mechanistic Causes Behind Adverse Cardiovascular and Cancer Health
3. Comparison of atrial fibrillation prevalence and in-hospital cardiovascular outcomes between patients undergoing allogeneic versus autologous hematopoietic stem cell transplantation: insights from the national inpatient sample
4. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
5. Radiation Management for Breast Cancer After Neoadjuvant Therapy
6. The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
7. A cancer disparities curriculum in a hematology/oncology fellowship program
8. Clinical markers of immunotherapy outcomes in advanced sarcoma
9. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer
10. Characterization of inflammatory changes in the breast cancer associated adipose tissue and comparison to the unaffected contralateral breast
11. Differences in breast tumor response to neoadjuvant chemotherapy by race – Is obesity the key?
12. Supplementary Figure 8 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
13. Supplementary Table 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
14. Supplementary Figure 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
15. Supplementary Figure 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
16. Supplementary Figure 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
17. Supplementary Figure 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
18. Supplementary Table 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
19. Supplementary Figure 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
20. Data from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
21. Supplementary Table 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
22. Supplementary Table 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
23. Supplementary Figure 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
24. Supplementary Figure 7 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
25. Supplementary Table 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
26. Supplementary Table 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
27. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
28. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
29. Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton’s Tyrosine Kinase
30. EVERYTHING YOU NEED TO KNOW ABOUT MENTORING TO ACHIEVE YOUR CAREER GOALS: A COMPREHENSIVE MENTORSHIP WORKBOOK.
31. Where the Sidewalk Ends: Parenting as a trainee during COVID-19
32. Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis
33. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer
34. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
35. Abstract P1-01-06: Differences in breast tumor response to neoadjuvant chemotherapy by race- Is obesity the key?
36. Abstract P4-02-17: Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in early-stage HER2-negative breast cancer: a US National Cancer Database analysis
37. Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven't Found What We're Looking For.
38. Additional file 1 of Clinical markers of immunotherapy outcomes in advanced sarcoma
39. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination
40. Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens
41. CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
42. COMPARISON OF IN-HOSPITAL CARDIOVASCULAR OUTCOMES BETWEEN PATIENTS UNDERGOING ALLOGENEIC VERSUS AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
43. TIPS FOR NAVIGATING THE ASCO ANNUAL MEETING AS A TRAINEE OR EARLY-CAREER ONCOLOGIST: FOUR PERSPECTIVES ON MAKING THE MOST OF YOUR TIME AT ASCO23.
44. 687 MDSC gene expression analysis in patients with cancer and the response to inhibition of Bruton's tyrosine kinase
45. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
46. Association of pathological complete response rates and TILs in triple-negative breast cancer patients.
47. BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer
48. Abstract PS13-46: Immunomodulation with dexamethasone in neoadjuvant chemotherapy for triple negative breast cancer
49. Triple-negative breast cancer: promising prognostic biomarkers currently in development
50. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.